Stereotaxis, Inc. (STXS)
$
2.85
-0.03 (-1.05%)
Key metrics
Financial statements
Free cash flow per share
-0.0906
Market cap
260.6 Million
Price to sales ratio
8.1929
Debt to equity
0.8482
Current ratio
1.0557
Income quality
0.3127
Average inventory
9.7 Million
ROE
-2.1937
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stereotaxis, Inc. designs, manufactures, and markets a range of robotic systems, instruments, and information solutions for interventional laboratories both in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, enabling physicians to conduct complex interventional procedures with image-guided catheter and guidewire delivery to treatment sites within the heart. The company reported a gross profit ratio of 0.54 reflecting the efficiency of its production and sales operations. It also generated an interest income of $694,000.00 showcasing its financial investments. The operating expenses reach $39,333,000.00 which cover various operational costs incurred, while the selling, general, and administrative expenses amounted to $29,573,000.00 indicating its operational overhead. Additionally, Stereotaxis offers innovations such as Odyssey, a real-time information solution for procedure management, and the Stereotaxis Imaging Model S X-ray system, designed for robotic interventional operating rooms. The company provides an array of disposables and accessories, including QuikCAS automated catheter advancement disposables and several advanced steerable tip catheters for electrophysiology. In the investment landscape, the stock is affordable at $2.85 making it an attractive option for budget-conscious investors. With a market capitalization of $257,869,479.00 the company is recognized as a small-cap player within the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. The stock experiences a low average trading volume of 504,317.00 suggesting lower market activity around it. Moreover, Stereotaxis, Inc. operates within the Healthcare sector, driving both innovation and growth while also forming strategic collaborations, such as the one with Osypka AG, to develop advanced magnetic ablation catheters utilizing its robotic technology.
Is Stereotaxis, Inc. (STXS) a good investment?
Investing in Stereotaxis, Inc. (STXS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Stereotaxis, Inc. (STXS)'s stock forecast?
Analysts predict Stereotaxis, Inc. stock to fluctuate between $1.54 (low) and $3.05 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Stereotaxis, Inc.'s market capitalization?
As of 2025-09-12, Stereotaxis, Inc.'s market cap is $257,869,479, based on 90,480,519 outstanding shares.
How does Stereotaxis, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Stereotaxis, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Stereotaxis, Inc. (STXS) stock?
To buy Stereotaxis, Inc. (STXS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STXS. Place an order (Market, Limit, etc.).
What is the best time to invest in Stereotaxis, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Stereotaxis, Inc. stock ever split?
Stereotaxis, Inc.'s last stock split was 137:125 on 2013-11-04.
How did Stereotaxis, Inc. perform in the last earnings report?
Revenue: $26,918,000 | EPS: -$0.30 | Growth: 11.11%.
Where can I find Stereotaxis, Inc.'s investor relations reports?
Visit https://www.stereotaxis.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Stereotaxis, Inc.?
You can explore historical data from here
What is the all-time high and low for Stereotaxis, Inc. stock?
All-time high: $9.94 (2021-08-10) | All-time low: $1.33 (2023-08-08).
What are the key trends affecting Stereotaxis, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.
globenewswire.com
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine.
seekingalpha.com
Stereotaxis, Inc. (NYSE:STXS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Operator Good afternoon.
zacks.com
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.07 per share a year ago.
globenewswire.com
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world's first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.
globenewswire.com
ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at a price per share of $2.00. The financing is being led by a strategic industry partner along with participation from a select group of institutional investors.
zacks.com
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
seekingalpha.com
I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin disposables and platform launches fueling a shift to an annuity-like model. Consensus underestimates top-line growth; I model $51M FY26E revenue, supported by robust operating momentum and innovation pipeline.
seekingalpha.com
Stereotaxis, Inc. (NYSE:STXS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Josh Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2025 Earnings Conference Call.
globenewswire.com
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37th Annual ROTH Conference in Dana Point, California.
See all news
